<DOC>
	<DOCNO>NCT02025985</DOCNO>
	<brief_summary>The primary trial objective determine efficacy KPT-330 ( selinexor ) patient advance metastatic gynaecological cancer disease control rate ( complete response ( CR ) partial response ( PR ) stable disease ( SD ) least 12 week , assess accord RECIST 1.1 criterion ) .</brief_summary>
	<brief_title>Phase II Study KPT-330 ( Selinexor ) Female Patients With Advanced Gynaecologic Malignancies &amp; Metastatic Breast Cancer</brief_title>
	<detailed_description>There two different dose schedule ovarian cancer patient . Two additional treatment schedule explore ovarian cohort optimize dose schedule patient population ovarian carcinoma . Two parallel cohort patient breast carcinoma also enrol .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Ovarian , fallopian tube peritoneal carcinoma : platinum refractory platinum resistant patient , receive ≥ 1 line chemotherapy relapse disease ( i.e. , ≥2 line chemotherapy total ) . Endometrial carcinoma : patient must receive ≥ 1 line chemotherapy relapse advanced ( stage IV , IIIc ) disease . Cervical carcinoma : patient must receive ≥ 1 line chemotherapy relapse advanced ( stage IVb ) disease . Breast cancer : adenocarcinoma breast metastatic locally advanced disease amenable curative resection curative treatment . Breast cancer : Patients must receive ≥ 1 line endocrine treatment chemotherapy metastatic disease applicable respective breast cancer subtype . Breast cancer : Patient must either triple negative cancer hormone receptor positive ( i.e. , ER+ and/or PR+ ) HER2 negative . Must either measurable disease ( RECIST 1.1 ) evaluable disease outside irradiated field CT/MRI . A rise CA125 tumor marker alone sufficient . ECOG performance status 01 . Life expectancy least 12 week . Able swallow retain oral medication . Evidence complete partial bowel obstruction . Gynecological cancer : All nonepithelial cancer ovary , fallopian tube , peritoneum , endometrium cervix well neuroendocrine tumor exclude . Radiation ( except plan ongoing palliative radiation bone outside region measurable disease ) ≤ 3 week prior C1D1 . Chemotherapy , immunotherapy systemic anticancer therapy ≤ 3 week prior C1D1 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Karyopharm</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Selinexor</keyword>
	<keyword>SIGN</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>SINE™</keyword>
	<keyword>breast cancer</keyword>
	<keyword>HER2 negative</keyword>
</DOC>